Dr. Chethan Dev is an experienced endocrinologist. He earned his MBBS from Bangalore Medical College and completed his MD in General Medicine at Assam Medical College,later obtaining his DNB in Endocrinology from CARE Hospitals, Hyderabad.
He has over six years of teaching experience as Assistant and Associate Professor in various medical colleges.
Dr. Dev focuses on diabetes, thyroid, pituitary and adrenal diseases, and metabolic bone disorders, advocating for a patient-centered approach.He contributes to the field through clinical work and education.
Adult Endocrinology
- Diabetes Mellitus (Type 1, Type 2, and Gestational Diabetes)
- Thyroid Disorders (Hypothyroidism, Hyperthyroidism, Nodules)
- Bone Health: Osteoporosis, Osteopenia, Skeletal Dysplasias
- Pituitary Disorders: Acromegaly, Cushing’s Syndrome, Hypopituitarism
- Adrenal Disorders: Hypercortisolism, Hypocortisolism, CAH, Conn’s Syndrome
- Gonadal Disorders: Male & Female Infertility, PCOD
- Endocrine causes of Electrolyte Imbalances (Sodium & Potassium disturbances)
Pediatric Endocrinology
- Growth Disorders
- Pubertal Issues
- Disorders of Sexual Development (DSD)
Endocrine Malignancies
- Thyroid Nodules and Thyroid Cancer
- Pituitary Tumors
- Adrenal Malignancies
DNB (ENDOCRINOLOGY)
- 2012 Participated and received 3rd prize for paper presentation “A STUDY OF SYSTOLIC AND DIASTOLIC DYSFUNCTION IN NORMOTENSIVE ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES MELLITUS” in APICON 2012, Jorhat, Assam.
- 2012 Participated and received 2nd prize for poster presentation “A STUDY OF SYSTOLIC AND DIASTOLIC DYSFUNCTION IN NORMOTENSIVE ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES MELLITUS” in APICON 2012, Jorhat, Assam.
- DIABETES
- THYROID
- OSTEOPOROSIS
- “CLINICAL PROFILE OF PATIENTS WITH DIABETES MELLITUS ATTENDING TERTIARY CARE HOSPITAL” in INDIAN JOURNAL OF EMERGENCY MEDICINE (IJEM) VOL4 NO4 OCT-DEC 2018
- “A TRI PRONG APPROACH IN THE MANAGEMENT OF INSULIN AUTOIMMUNE SYNDROME” in INDIAN J ENDOCRINOLOGY AND METABOLISM VOL 26 (SUPPL 1); MAR 2022 PMC: 9067765
- “SGLT2I INDUCED REFRACTORY MYCOTIC INFECTIONS… ORGAN VS TISSUE”. ANNALS OF DIABETES, METABOLIC DISORDERS & CONTROL. 2022; 3(2):130.
CLINICAL RESEARCH EXPERIENCE:
Clinical Trials
- Protocol No : NN9924-4635 (PIONEER-PLUS)- Oral Semaglutide dose escalation
- Protocol No : LPS16665_SAFEGUARD-Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Anti-hyperglycemic Drugs
- Protocol No: I8F-MC-GPHK(a) SURMOUNT (Tirzapetide- Obesity Study)”
- ASSOCIATION OF PYSICIANS OF INDIA,
- ENDOCINE SOCIETY OF INDIA,
- INDIAN SOCIETY FOR BONE AND MINERAL RESEARCH
